Advanced Therapeutic Approaches in Immune Thrombocytopenic Purpura (ITP)
ITP is characterized by immune-mediated platelet destruction leading to increased bleeding risk. Treatment strategies aim to raise platelet counts, prevent severe bleeding, and improve quality of life. This comprehensive guide presents current evidence-based approaches for hematology specialists managing adult and pediatric ITP patients.
First-Line and Second-Line ITP Treatment Approaches
Strategic Treatment Selection in ITP Management

Individualized Therapy
Treatment tailored to bleeding risk, age, and comorbidities
Evidence-Based Protocols
Following ASH 2019 guidelines for optimal sequencing
Risk-Benefit Assessment
Weighing efficacy against side effects and cost
Multiple Mechanisms
Targeting platelet destruction and/or production pathways
The therapeutic approach to ITP requires strategic decision-making based on disease severity, patient characteristics, and treatment response patterns. First-line agents provide rapid response but limited durability, while second-line options offer sustained effect with higher cost and monitoring requirements.
Future Directions and Emerging Therapies in ITP

1

1
FcRn Inhibitors
Novel mechanism targeting neonatal Fc receptor to reduce IgG autoantibody half-life

2

2
BTK Inhibitors
Disrupts B-cell receptor signaling to prevent autoantibody production

3

3
Precision Medicine
Biomarker development to predict treatment response and guide therapy selection

4

4
Combination Approaches
Synergistic therapy targeting multiple pathways simultaneously
Despite advancements, challenges remain in managing refractory ITP. Emerging therapies show promise in clinical trials but face regulatory hurdles. Healthcare disparities and cost concerns continue to impact treatment accessibility, particularly for patients requiring long-term therapy with expensive agents like TPO-RAs ($30,000-$50,000 annually).